Pregnancy is a period in which physiological, psychological and social changes are experienced in female life. These changes can cause various mental illnesses during and after pregnancy. Postpartum depression is commonly seen in the perinatal period. Postpartum depression is an important cause of morbidity and mortality for mother and baby. A major depressive episode with peripartum onset is defined as postpartum depression when it occurs during pregnancy or up to 4 weeks of postpartum. The frequency of the disease is extremely high. Biological, psychological and sociocultural factors have been reported to be effective in the etiology. It presents with major depression symptoms such as depression, anhedonia, thoughts of guilt, irritability, concentration disorder, psychomotor agitation, psychomotor retardation, sleep disorder, appetite and weight changes. There are many different options in the treatment. Most of these options have been adapted from the treatment of major depression. Serotonin reuptake inhibitors (SSRI), serotonin noradrenaline reuptake inhibitors (SNRIs), tricyclic antidepressants, estradiol, progesterone, psychotherapies, electronvulsive therapy and brexanolone may be used in the treatment. Brexanolone is a promising new drug in the treatment of postpartum depression. It is the only treatment in postpartum depression that has received special indication. This review aims to investigate the recent developments in the etiology, diagnosis and treatment of postpartum depression in the light of current data.
|Konular||Sağlık Bilimleri ve Hizmetleri|
: 1 Temmuz 2019
|Vancouver||ERDOĞAN A , HOCAOĞLU Ç . Doğum Sonrası Depresyonun Tanı ve Tedavisi: Bir Gözden Geçirme. Mustafa Kemal Üniversitesi Tıp Dergisi. 2020; 37-31.|